Europe’s largest medicinal cannabis registry, Project Twenty21, is beginning to gather pace. Steve Jones spoke to Drug Science chief executive David Badcock ahead of the publication of its first data set.

In late February, the first data from what has been touted as Europe’s largest medicinal cannabis recruitment registry, Project Twenty21, is expected to be released.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

The analysis will be published in the Journal of Psychopharmacology, and contain analysis from around 250 patients. The initial findings, while still under wraps, have been described as “interesting”.

Drug Science CEO David Badcock: ‘The data will be a great starting point.’

For UK-based Project Twenty21, or T21 as it is known, the publication will mark the first steps on a road to further the understanding of medicinal cannabis, and to demonstrate its efficacy and safety.

Through continuous gathering of real-world evidence, project leaders want to build a compelling case for medicinal cannabis to be more widely prescribed by GPs and, ultimately, to be available on Britain’s National Health Service.

“The data is going to be a great starting point,” said David Badcock, chief executive of Drug Science, the organisation behind T21.

“It’s the first data set that we have and it shows some interesting things. We’re really excited.”

The intention is to develop and publish rolling data “every few months”.

Steve has reported for a number of consumer and B2B titles over a journalism career spanning more than three decades. He is a regulator contributor to health journal, The Medical Republic, writing on...